Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

MILWAUKEE , Dec. 15, 2025 /PRNewswire/ -- The Ademi Firm is investigating Generation Bio (Nasdaq: GBIO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XOMA Royalty Corporation. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Generation Bio Co. (NASDAQ: GBIO) to XOMA Royalty Corporation for $4.2913 per share and one non-transferable contingent value right per share entitling holders to receive potential payments under certain conditions is fair to Generation Bio shareholders. Halper Sadeh encourages Generation Bio shareholders to click here to learn more about their legal rights and options or contact Danie.

- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna -

CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results.

• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company's Board of Directors.

CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 reverse stock split of the issued shares of the Company's common stock (“Reverse Stock Split”), effective at 5:00 pm Eastern Time on July 21, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 4, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.